Home > Product Overview > Nemonoxacin

New treatment for drug-resistant bacterial infection: Taigexyn® (Nemonoxacin)

The novel antibiotic Taigexyn® (Nemonoxacin) is TaiGen’s first approved drug. Drug-resistant bacterial infection is a global crisis, as standard treatments are becoming less and less effective against the types of infections commonly encountered in hospital or community environments. The size of the global antibiotic market is around US$1150 billion in 2017 and will likely grow as the problem of drug resistance increases. It is estimated that the size of global antibiotic market will reach USD$1686 billion in 2026 and the CAGR is 4.3%.

Taigexyn® (Nemonoxacin) was acquired under license by TaiGen 2004 from Procter & Gamble Pharmaceuticals. At the time of acquisition, the drug had completed Phase Ia clinical trial. Further development work has since has been undertaken by TaiGen's clinical team, including expanding the range of possible therapeutic applications, patent protection expansion, and conducting additional clinical trials.

Taigexyn is a novel non-fluorinated quinolone antibacterial drug with once-a-day dosing, available in both oral and intravenous formulations. Clinical trials have shown that Taigexyn is effective against increasingly virulent drug-resistant bacteria including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), Acinetobacter baumannii, and others. With current indications of community-acquired pneumonia (CAP), TaiGen plans on adding indications for the drug in the future, including in the fields of diabetic foot infection (DFI), skin infections and nosocomial pneumonia. All Taigexyn patents and intellectual property are 100 percent owned by TaiGen.